Botulinum toxin type A

Generic Name
Botulinum toxin type A
Brand Names
Botox, Botox Cosmetic, Dysport, Jeuveau, Xeomin, Nuceiva
Drug Type
Biotech
Chemical Formula
-
CAS Number
93384-43-1
Unique Ingredient Identifier
0A6JH35GMQ
Background

In 2002, botulinum toxin A, also known as onabotulinumtoxinA or Botox, was the first type A botulism toxin to be introduced into the market for cosmetic use. With a wide variety of applications and favourable safety profile, Botulinum toxin A injection is a minimally invasive and promising treatment for cosmetic imperfections, muscle spasms, and other conditions. A popular use for Botox is the treatment of facial wrinkles and lines, however, there are many uses for the botulinum toxin A in the treatment of dystonia, incontinence, migraine, blepharospasm, and hyperhidrosis.

Indication

Botulinum toxin A is indicated for a variety of conditions, depending on the preparations. Cosmetically, it is used for the treatment of facial fine lines and wrinkles, specifically for upper facial rhytides, including forehead, lateral canthus, and glabellar lines.

In addition to the above indications, botulinum toxin A is used for the following conditions: treatment of adults with symptomatic overactive bladder with or without incontinence, treatment of incontinence in adult patients who are not candidates for anticholinergic therapy, treatment of Neurogenic Detrusor Overactivity (NDO) in patients over 5 years who cannot undergo anticholinergic therapy. Botulinum toxin A is indicated for the prevention of chronic migraines, for the treatment of muscle spasms, cervical dystonia, axillary hyperhidrosis, strabismus, and disorders of the 7th cranial nerve.

Off-label, botulinum toxin A is used for a variety of conditions such as temporomandibular joint (TMJ) disorders and myofascial pain, neurogenic thoracic outlet syndrome, epicondylitis, post-stroke pain, post-herpetic neuralgia, diabetic neuropathy, trigeminal neuralgia, neuropathic pain, spinal cord injury, and bladder pain.

Associated Conditions
Bladder pain, Blepharospasm, Cervical Dystonia, Chronic Migraine, Diabetic Neuropathies, Epicondylitis, Equinus deformity of foot, acquired, Facial Skin Wrinkles, Glabellar Frown Lines (GL), Lower Limb Spasticity, Myofascial Pain Syndrome, Neurogenic Detrusor Overactivity, Neurogenic Thoracic Outlet Syndrome, Overactive Bladder Syndrome (OABS), Post Stroke Pain, Postherpetic Neuralgia, Sialorrhea, Spasticity, Spinal Cord Injuries, Strabismus, TMJ Disorders, Trigeminal Neuralgia (TN), Upper Limb Spasticity, Urinary Incontinence (UI), Hypertonicity disorders of the 7th nerve, Moderate Glabellar Frown Lines (GL), Severe Glabellar Frown Lines (GL), Severe axillary hyperhidrosis
Associated Therapies
-

Botulinum Toxin Type A Injection After Topical Anesthesia Versus Petrolatum Ointment

First Posted Date
2019-01-10
Last Posted Date
2020-06-18
Lead Sponsor
The University of Texas Health Science Center, Houston
Target Recruit Count
14
Registration Number
NCT03799484
Locations
🇺🇸

Robert Cizik Eye Clinic, Houston, Texas, United States

Improved Sitting Balance: Body Functions to Participation

Completed
Conditions
First Posted Date
2018-12-27
Last Posted Date
2019-08-21
Lead Sponsor
Kocaeli University
Target Recruit Count
29
Registration Number
NCT03788317
Locations
🇹🇷

Kocaeli University, Kocaeli, Turkey

Dry Needling and Botulinum Toxin in the Management of Poststroke Spasticity

First Posted Date
2018-11-20
Last Posted Date
2018-12-19
Lead Sponsor
Sultan Abdulhamid Han Training and Research Hospital, Istanbul, Turkey
Target Recruit Count
30
Registration Number
NCT03747900
Locations
🇹🇷

Sultan Abdulhamid Han Training and Research Hospital, Istanbul, Uskudar, Turkey

The Effect of Botulinum Toxin A In Patients With Excessive Gingival Display With And Without Zinc Supplementation

First Posted Date
2018-10-24
Last Posted Date
2022-05-20
Lead Sponsor
Cairo University
Target Recruit Count
26
Registration Number
NCT03717987
Locations
🇪🇬

Faculty of Dentistry, Cairo University, Cairo, Egypt

Effect of Botulinum Toxin Type A Associated With Physical Therapy on Children With Spastic Cerebral Palsy

First Posted Date
2018-10-12
Last Posted Date
2018-10-12
Lead Sponsor
University of Nove de Julho
Target Recruit Count
24
Registration Number
NCT03704155

Botox or Botox With Esophageal Dilation in Patients With Achalasia

First Posted Date
2018-08-31
Last Posted Date
2024-05-16
Lead Sponsor
Vanderbilt University Medical Center
Target Recruit Count
50
Registration Number
NCT03654066
Locations
🇺🇸

Vanderbilt University Medical Center Endoscopy Laboratory, Nashville, Tennessee, United States

The Objective of This Study is to Evaluate the Efficacy and Safety of Botulax® in Patients With Essential Blepharospasm.

Phase 4
Completed
Conditions
Interventions
First Posted Date
2018-08-22
Last Posted Date
2018-08-22
Lead Sponsor
Hugel
Target Recruit Count
249
Registration Number
NCT03641950
Locations
🇰🇷

Hugel, Seoul, Korea, Korea, Republic of

The Effect of Abobotulinum Toxin A on the Symptoms of Raynaud's Phenomenon

First Posted Date
2018-08-21
Last Posted Date
2021-06-30
Lead Sponsor
University of Central Florida
Target Recruit Count
3
Registration Number
NCT03639766
Locations
🇺🇸

UCF Health Lake Nona Office, Orlando, Florida, United States

Trigonal vs Non Trigonal Botox Injection in OAB.

First Posted Date
2018-05-22
Last Posted Date
2018-10-09
Lead Sponsor
Mansoura University
Target Recruit Count
80
Registration Number
NCT03533062

Integrated Management of Pronation Deformity in Cerebral Palsy

First Posted Date
2018-03-21
Last Posted Date
2020-04-16
Lead Sponsor
Kocaeli University
Target Recruit Count
35
Registration Number
NCT03472261
Locations
🇹🇷

Kocaeli University, Kocaeli, Turkey

© Copyright 2024. All Rights Reserved by MedPath